XML 30 R21.htm IDEA: XBRL DOCUMENT
v3.22.1

Segment Data (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2022
Segment Reporting [Abstract] |
Revenue from External Customers by Geographic Area | Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.
| Three Months Ended March 31,
(Millions of dollars) | 2022 |  | 2021
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions | $ | 588 |  |  | $ | 450 |  |  | $ | 1,038 |  |  | $ | 531 |  |  | $ | 468 |  |  | $ | 999 |
Medication Management Solutions | 461 |  |  | 143 |  |  | 604 |  |  | 440 |  |  | 126 |  |  | 566 |
Diabetes Care | 140 |  |  | 133 |  |  | 273 |  |  | 148 |  |  | 135 |  |  | 284 |
Pharmaceutical Systems | 125 |  |  | 376 |  |  | 501 |  |  | 100 |  |  | 361 |  |  | 462 |
Total segment revenues | $ | 1,314 |  |  | $ | 1,102 |  |  | $ | 2,416 |  |  | $ | 1,220 |  |  | $ | 1,091 |  |  | $ | 2,311 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 618 |  |  | $ | 532 |  |  | $ | 1,150 |  |  | $ | 454 |  |  | $ | 807 |  |  | $ | 1,261 |
Biosciences | 129 |  |  | 206 |  |  | 335 |  |  | 121 |  |  | 204 |  |  | 325 |
Total segment revenues | $ | 747 |  |  | $ | 738 |  |  | $ | 1,485 |  |  | $ | 576 |  |  | $ | 1,010 |  |  | $ | 1,586 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 268 |  |  | $ | 72 |  |  | $ | 340 |  |  | $ | 227 |  |  | $ | 65 |  |  | $ | 292 |
Peripheral Intervention | 240 |  |  | 210 |  |  | 450 |  |  | 222 |  |  | 198 |  |  | 420 |
Urology and Critical Care | 239 |  |  | 82 |  |  | 320 |  |  | 217 |  |  | 82 |  |  | 298 |
Total segment revenues | $ | 746 |  |  | $ | 364 |  |  | $ | 1,111 |  |  | $ | 666 |  |  | $ | 345 |  |  | $ | 1,011 |
Total Company revenues | $ | 2,807 |  |  | $ | 2,204 |  |  | $ | 5,011 |  |  | $ | 2,462 |  |  | $ | 2,446 |  |  | $ | 4,907 |
| Six Months Ended March 31,
(Millions of dollars) | 2022 |  | 2021
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions | $ | 1,207 |  |  | $ | 915 |  |  | $ | 2,122 |  |  | $ | 1,099 |  |  | $ | 908 |  |  | $ | 2,006 |
Medication Management Solutions | 945 |  |  | 286 |  |  | 1,231 |  |  | 917 |  |  | 278 |  |  | 1,196 |
Diabetes Care | 291 |  |  | 271 |  |  | 561 |  |  | 298 |  |  | 271 |  |  | 569 |
Pharmaceutical Systems | 228 |  |  | 670 |  |  | 898 |  |  | 180 |  |  | 621 |  |  | 801 |
Total segment revenues | $ | 2,671 |  |  | $ | 2,142 |  |  | $ | 4,813 |  |  | $ | 2,494 |  |  | $ | 2,078 |  |  | $ | 4,572 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 1,232 |  |  | $ | 1,062 |  |  | $ | 2,295 |  |  | $ | 1,469 |  |  | $ | 1,459 |  |  | $ | 2,928 |
Biosciences | 258 |  |  | 416 |  |  | 674 |  |  | 241 |  |  | 396 |  |  | 637 |
Total segment revenues | $ | 1,490 |  |  | $ | 1,478 |  |  | $ | 2,968 |  |  | $ | 1,710 |  |  | $ | 1,855 |  |  | $ | 3,565 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 549 |  |  | $ | 152 |  |  | $ | 701 |  |  | $ | 489 |  |  | $ | 135 |  |  | $ | 624 |
Peripheral Intervention | 457 |  |  | 407 |  |  | 863 |  |  | 454 |  |  | 392 |  |  | 846 |
Urology and Critical Care | 492 |  |  | 168 |  |  | 661 |  |  | 445 |  |  | 171 |  |  | 616 |
Total segment revenues | $ | 1,498 |  |  | $ | 727 |  |  | $ | 2,225 |  |  | $ | 1,388 |  |  | $ | 698 |  |  | $ | 2,086 |
Total Company revenues | $ | 5,659 |  |  | $ | 4,347 |  |  | $ | 10,006 |  |  | $ | 5,592 |  |  | $ | 4,631 |  |  | $ | 10,223 |
Financial Information for Company's Segments | Segment income for the three and six-month periods was as follows:
| Three Months Ended March 31, |  | Six Months Ended March 31,
(Millions of dollars) | 2022 |  | 2021 |  | 2022 |  | 2021
Income Before Income Taxes |  |  |  |  |  |  |
Medical (a) | $ | 615 |  |  | $ | 634 |  |  | $ | 1,331 |  |  | $ | 1,300 |
Life Sciences | 475 |  |  | 548 |  |  | 1,009 |  |  | 1,521 |
Interventional | 280 |  |  | 209 |  |  | 544 |  |  | 511 |
Total Segment Operating Income | 1,370 |  |  | 1,392 |  |  | 2,884 |  |  | 3,331 |
Integration and restructuring expense | (28) |  |  | (52) |  |  | (62) |  |  | (102) |
Net interest expense | (100) |  |  | (122) |  |  | (195) |  |  | (238) |
Other unallocated items (b) | (717) |  |  | (913) |  |  | (1,378) |  |  | (1,529) |
Total Income Before Income Taxes | $ | 525 |  |  | $ | 305 |  |  | $ | 1,248 |  |  | $ | 1,462 |
(a)The amounts for the three and six months ended March 31, 2022 include a noncash asset impairment charge of $54 million recorded to Cost of products sold in the Medical segment. (b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amounts for the three and six months ended March 31, 2021 also included pre-tax charges of $296 million recorded to Other operating expense, net related to certain product liability matters, including the related legal defense costs, which are further discussed in Note 4.

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration